Sairopa B.V., today announced it has achieved a milestone event in its exclusive clinical development and option agreement with Exelixis, Inc. involving ADU-1805, an innovative anti-SIRP? antibody ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback